ceo retir dplo co-found ceo phil hagerman retir effect
immedi somewhat abrupt transit place dplo appoint
jeff park interim ceo current member compani board
director former optumrx hagerman serv consult
compani throughout ensu search perman ceo like
complet next three six month remain board
director compani hold preconceiv notion interim ceo
jeff park like frontrunn given year experi pbm
industri align dplo recent shift strateg focu
rais target price greater clariti success
line visibl
preliminari outlook in-lin re-affirmed conjunct
announc dplo also unveil preliminari outlook
includ recent acquir np ldi also reaffirm previou
guidanc expect revenu rang
billion midpoint vs estimate billion ebitda rang
million million midpoint in-lin estimate
maintain ep estim guidanc par
reiter under-perform dplo share rose back news
enhanc visibl outlook manag success
plan note phil hagerman jeff park well cfo atul kavthekar
present week upcom investor confer although
news reinforc dplo lt pbm strategi follow recent acquisit
ldi np dplo pro forma net leverag ratio stand
follow six deal capit deploy like
focus de-lever imped abil compens
on-going lacklust organ trend risk includ shift fundament
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
diplomat pharmaci independ specialti pharmaci
dispens pharmaceut patient complex chronic
price jan rate under-perform target price analyst erin wright
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
cash-flow financ activ
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
expans current level ev/ebitda
estim
 close
weaker fundament perform sentiment could lead
downsid versu target price grey sky scenario
charl martineau univers toronto figur dplo organ acquir revenu
estim revenu acquisit
compani data credit suiss estim dollar million
compani mention price
